Related Experiment Videos
In vitro hydroxyurea decreases Th1 cell-mediated immunity.
1Department of Pediatrics, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA. adriana.weinberg@uchsc.edu
Clinical and Diagnostic Laboratory Immunology
|June 28, 2001
Summary
Hydroxyurea (HU) can impair T-cell immune responses by reducing lymphocyte proliferation and gamma interferon. This effect is reversible and occurs in both HIV-infected and uninfected individuals.
Area of Science:
- Immunology
- Pharmacology
Background:
- Hydroxyurea (HU) is a medication used for hematologic disorders and sometimes in combination therapy for human immunodeficiency virus (HIV) suppression.
- HU can exhibit toxicity towards rapidly dividing cells, including immune response effectors.
Purpose of the Study:
- To investigate the impact of Hydroxyurea on specific T-cell responses.
- To assess the effects of HU on lymphocyte proliferation and cytokine production.
Main Methods:
- Peripheral blood mononuclear cells (PBMCs) from HIV-infected patients and healthy controls were stimulated with microbial antigen and mitogen in the presence of varying HU concentrations (10–1,000 µM).
- Lymphocyte proliferation and cytokine production (Interferon-gamma, Interleukin-2, Interleukin-10) were measured.
Main Results:
- HU significantly decreased lymphocyte proliferation and gamma interferon production in PBMCs from both HIV-infected and uninfected individuals.
- Interleukin-2 and Interleukin-10 production remained unaffected by HU treatment.
- The inhibitory effect of HU was dependent on continuous drug exposure and was reversible upon drug removal.
Conclusions:
- Hydroxyurea treatment can suppress Th1-cell-mediated immune responses.
- These findings suggest potential implications for immune function in patients receiving HU-containing therapies.